• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® ADO CD73 Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Transcreener® cGAMP cGAS Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
      • Transcreener® GDP GTPase Assay Kits
      • Transcreener® UDP² Glycosyltransferase Assay
      • Transcreener® 2-5A OAS Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target Family
      • Kinase Assay Kits
      • ATPase Assay Kits
      • Glycosyltransferase Assay Kits
      • GTPase Assay Kits
        • GAP Assay Kits
        • GEF Assay Kits
      • Ligase and Synthetase Assay Kits
      • Methyltransferase Assay Kits
      • Phosphodiesterase Assay Kits
    • HTS Assays by Target
      • Adenosine Kinase Assay Kits
      • AMPK Assay Kits
      • CD39 Assay Kits
      • CD73 Assay Kits
      • cGAS Assay Kits
      • DDX3 Assay Kits
      • ENPP1 Assay Kits
      • EZH2 Assay Kits
      • IKK-beta Assay Kits
      • IRAK4 Assay Kits
      • JAK1 Assay Kits
      • JAK3 Assay Kits
      • NSP13 Assay Kits
      • NUDT5 Assay Kits
      • OAS Assay Kits
      • PKR Assay Kits
      • TBK1 Assay Kits
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Innate Immunity
    • ADK Activity Assays
    • AMPK Activity Assays
    • cGAS Activity Assays
    • CD73 Activity Assays
    • CD38 Activity Assay Services
    • CD39 Activity Assays
    • DDX3 Activity Assays
    • ENPP1 Activity Assays
    • IKK-beta Activity Assays
    • IRAK4 Activity Assays
    • JAK1 Activity Assays
    • JAK3 Activity Assays
    • NSP13 Activity Assays
    • OAS1 Activity Assays
    • PKR Activity Assays
    • TBK1 Activity Assays
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

TYK2 Inhibition Finally Comes of Age

by Bellbrook Labs / Tuesday, 01 February 2022 / Published in Emerging Targets, Innate Immunity
TYK2 Inhibition Discovery

Tyrosine kinase 2 (TYK2) was the first of the Janus family of non-receptor tyrosine kinases to be discovered. For three decades, the other members of this family, JAK1, JAK2, and JAK3, have dominated the research for inhibitors of autoimmune disease, largely because the effect upon them was more pronounced. They are called “Janus kinases” because they usually assemble and are activated in particular heterodimeric pairings, binding to the intracellular domains of specific cytokine receptors. Once active, a given JAK pair initiates several rounds of phosphorylation, resulting in the recruitment of a specific signal transducer and activator of transcription factors (STATs). Upon STAT phosphorylation, these particular STATs are sent to the nucleus to regulate genes involved in specific immune or hematopoietic responses.¹

While inflammatory cytokine signaling is essential in fighting off bacterial, fungal, or viral infection, it is usually transient and only sufficient to ward off the invaders. The T helper 17 branches of the immune system act by issuing pro-inflammatory cytokine messengers and are critical to fighting off pathogens. In fact, loss of function mutations in TYK2 has been found to leave patients wide open to viral and mycobacterial infections. However, when such signaling becomes constitutive, autoimmune diseases can arise. TYK2 involvement in excessive JAK signaling is associated with psoriasis, psoriatic arthritis, Crohn’s disease, axial spondyloarthritis, and systemic lupus erythematosus. In psoriasis, IL-17 produced by TYK2/JAK2 signaling in mature Th17 cells provokes target tissues to release IL-23, and this IL-23 returns to re-stimulate the same T-cell signaling in a vicious cycle of inflammation. Similarly, TYK2/JAK2 signaling in Th1 cells is stimulated by IL-12 binding, initiating a cell-mediated response. Interferon-alpha and beta binding initiate TYK2/JAK1 assembly and signal transduction.²

TYK2 Specific Inhibitors

Since phosphorylation, instigated by the given JAK pair, is required to send STATs to the nucleus, inhibition of ATP binding was the first target sought to abrogate signaling in the JAK-STAT system. The first such inhibitor, Tofacitinib, was discovered at the NIH and developed by Pfizer. It competes for attachment at the JAK ATP binding site, preventing JAK-mediated phosphorylation. This is all well and good. However, since this ATP binding site is common to all the JAKs, depending on concentration, various JAK inhibitors affected all the JAKS. While, for instance, rheumatoid arthritic symptoms could be dampened, other side effects often interfered with continuous treatment.³

Over time, ever more precise modifications have been made to inhibit only TYK2 specifically. However, one of the unfortunate impediments to developing specific TYK2 inhibitors was the slight molecular difference between the TYK2 ATP binding site in all preclinical test species and in humans. This produced a distorted view of the potency of various inhibitors until it was characterized and modified by Brian Gerstenberger’s group at Pfizer.4 With this knowledge in hand, his group, has produced a highly selective TYK2 ATP binding site inhibitor (PF06826647) that promises to deter autoimmune disease with exquisite precision.5 The Wrobleski group at Bristol-Myers Squibb has produced an inhibitor (BMS-986165) that binds the adjacent (pseudokinase) motif in TYK2, resulting in novel allosteric interference with ATP binding. This particular inhibitor is over 10,000 times more sensitive for TYK2 than any other JAK.6

Hopefully, these recent exciting developments will, at last, deliver on the promise of precise TYK2 targeted therapy for autoimmune disease.

References

1. Hromadova, D. et al. (2021) From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases. Frontiers in Genetics, Review, 05 July 2021. https://doi.org/10.3389.fgene.2021.685280

2. Ghoreschi, K. et al. (2021) TYK2 inhibition and its potential in the treatment of chronic inflammatory immune diseases. Journal of the German Society of Dermatology, 19(10), 1409-1420. https://doi.org/10.1111/ddg.14585

3. Gonciarz, M. et al. (2021) TYK2 as a target in the treatment of autoimmune and inflammatory diseases. Immunotherapy, 13(13), Review. https://doi.org/10.2217/imt-2021-0096

4. Gerstenberger, B. et al. (2020) Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross-Species Potency Differences. Nature Scientific Reports, 10, Article number: 8974
https://www.nature.com/articles/s41598-020-65762-y

5. Gerstenberger, B. et al. (2020) Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. Journal of Medicinal Chemistry, 63(22), 13561-13577.
https://doi.org/10.1021/acs.jmedchem.0c00948

6. Wrobleski, S. et al. (2019) Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. Journal of Medicinal Chemistry, 62(20), 8973-8995. https://doi.org/10.1021/acs.jmedchem.9b00444

Tagged under: drug discovery services, Innate Immunity, Transcreener ADP Kinase Assay, TYK2 Inhibitor

What you can read next

Targeting Adenosine Kinase In the Fight Against Neurological Disorders
Targeting Adenosine Kinase in the Fight Against Neurological Disorders
PRMT5 Role with Macrophages
PRMT5 is Innately Interesting
Ectonucleotidases: An Outside Chance for Drug Development

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • Info book on cancer and RAFK1's relation

    RAF1 & Immunity: A Future Model For Cancer Research?

    RAF1, also known as c-Raf, is a member of the R...
  • OAS1 The Cost of Host Defense

    OAS1: The Cost of Host Defense

    OAS1 (Oligoadenylate synthetase 1) is induced b...
  • Scientist Studying DDX41

    DDX41 as a Sensor, Suppressor, and Modulator

    DDX41 [DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 4...
  • Scientist Studying ALKPK1

    The Role of ALPK1 in Health and Disease

    ALPK1 (Alpha Kinase 1) is an atypical serine/th...
  • DHX36 RNA Helicase Unwinds G4 RNA Structures

    Resolving the Many Roles of DHX36

    While most researchers are familiar with canoni...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2022 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP